Education
About Us
Working with TipRanks
Follow Us
Mochida Pharmaceutical Co., Ltd. (DE:MFY)
FRANKFURT:MFY
MFY Stock Chart & Stats
Day’s Range― - ―
52-Week Range€16.60 - €22.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€616.16M
Enterprise Value€60.80B
Total Cash (Recent Filing)€53.58B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)18.1
Beta0.52
Next Earnings
Aug 01, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 28, 2025Dividend Yield2.79%
Share Statistics
EPS (TTM)0.01
Shares Outstanding36,390,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.84
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Mochida Pharmaceutical Co., Ltd. News
PremiumCompany Announcements
Mochida Pharmaceutical Announces Leadership Changes to Strengthen Management
PremiumCompany Announcements
Mochida Pharmaceutical Continues Takeover Defense Policy
PremiumCompany Announcements
Mochida Pharmaceutical Reports Strong Financial Growth for FY 2025PremiumCompany Announcements
Mochida Pharmaceutical Unveils 25-27 Medium-term Growth Strategy
PremiumCompany Announcements
Mochida Pharmaceutical Reports Robust Profit Growth for 2024
PremiumCompany Announcements
Mochida Pharmaceutical Reports Stable Financial PerformanceOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.06%
Mutual Funds
― Other Institutional Investors
94.47% Public Companies and
Individual Investors
MFY FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was €16.60 and its highest was €22.40 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is €616.16M.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 01, 2025 which is in 56 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on May 12, 2025. The company reported €0.014 earnings per share for the quarter, beating the consensus estimate of N/A by €0.014.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. pays a Annually dividend of €0.245 which represents an annual dividend yield of 2.79%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of €0.014 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.075%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in DE:MFY
Company Description
Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―